NADAC acquisition cost data for ASHLYNA 0.15-0.03-0.01 MG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 68462064691 | $0.3223 | 2022-12-21 | Rx |
| 68462064693 | $0.3223 | 2022-12-21 | Rx |
| 68462064691 | $0.3223 | 2022-12-21 | Rx |
| 68462064693 | $0.3223 | 2022-12-21 | Rx |
Generic: L-Norgest/E.Estradiol-E.Estrad | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $312.9K | 2,388 | 966 | $1.46 |
| 2020 | $266.6K | 2,202 | 937 | $1.33 |
| 2021 | $117.2K | 1,148 | 505 | $1.12 |
| 2022 | $100.8K | 1,061 | 476 | $1.03 |
| 2023 | $86.7K | 1,105 | 463 | $0.8569 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $9.4K | 77 | 32 |
| New York | $7.8K | 86 | 35 |
| Ohio | $5.9K | 65 | 28 |
| Texas | $5.7K | 50 | 20 |
| Pennsylvania | $5.5K | 101 | 43 |
| North Carolina | $4.2K | 53 | 20 |
| Florida | $3.5K | 46 | 17 |
| Kentucky | $3.0K | 34 | 14 |
| Michigan | $3.0K | 47 | 20 |
| Oklahoma | $2.7K | 30 | 11 |
| Washington | $2.7K | 34 | 14 |
| Indiana | $2.6K | 26 | N/A |
| Virginia | $2.4K | 46 | 21 |
| Louisiana | $2.2K | 31 | 15 |
| Missouri | $1.7K | 24 | 12 |
| Wisconsin | $1.6K | 19 | N/A |
| Colorado | $1.5K | 24 | N/A |
| West Virginia | $1.4K | 12 | N/A |
| Alabama | $1.3K | 15 | N/A |
| Utah | $1.2K | 15 | N/A |
| Delaware | $1.2K | 18 | N/A |
| Minnesota | $1.2K | 15 | N/A |
| Arizona | $1.2K | 17 | N/A |
| Illinois | $1.1K | 16 | N/A |
| Maine | $997.39 | 12 | N/A |
| Oregon | $925.18 | 24 | N/A |
| South Carolina | $889.38 | 14 | N/A |
| New Hampshire | $884.09 | 14 | N/A |
| Connecticut | $864.02 | 11 | N/A |
| Iowa | $850.33 | 15 | N/A |
| Georgia | $741.24 | 11 | N/A |
| Massachusetts | $721.63 | 17 | N/A |
| Kansas | $638.30 | 12 | N/A |
| Idaho | $517.18 | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.